Objectives: Combination therapy is an important option in the fight against Gram-negative 'superbugs'. This study systematically investigated bacterial killing and the emergence of polymyxin resistance with polymyxin B and chloramphenicol combinations used against New Delhi metallo-b-lactamase (NDM)-producing MDR Klebsiella pneumoniae.
Introduction
Since the first report of New Delhi metallo-b-lactamase (NDM)-producing Klebsiella pneumoniae in December 2009, a major international crisis has arisen due to the rapid spread of NDM-producing Enterobacteriaceae.
1,2 NDM-1 is a novel metallob-lactamase (28 kDa) encoded by the bla NDM-1 gene that can be disseminated via horizontal gene transfer (with a frequency of 10 24 -10 25 ). 1 -3 NDM-1 catalyses hydrolysis of the b-lactam ring and confers resistance to a wide range of b-lactams including cephalosporins, penicillins and carbapenems. 2 Typically, NDMproducing Enterobacteriaceae isolates are MDR and cannot be treated with commonly used antibiotics such as aminoglycosides and fluoroquinolones. 2 The intransigence to therapy of NDMproducing pathogens leads to prolonged illness, increased morbidity and mortality and higher economic costs. 4, 5 A recent report by the US CDC classified carbapenem-resistant Enterobacteriaceae (CRE) as an urgent threat to the antibiotic armamentarium. 6 CRE cause 9300 healthcare-associated infections in the USA per year, with the majority of these being due to Klebsiella spp. 6 Facing dwindling treatment options, clinicians have increasingly turned to polymyxins, which retain significant activity against NDM-producing pathogens, including K. pneumoniae. 1, 7 Two polymyxins are used clinically: colistin (polymyxin E; administered intravenously as its inactive prodrug colistin methanesulphonate) and polymyxin B. 8, 9 Polymyxins, which entered clinical use in 1959, target the negatively charged lipid A moiety of LPS in the outer membrane and as such are active only against Gram-negative bacteria. 10 Although polymyxins are active against NDM-producing K. pneumoniae, recent studies have shown that polymyxin resistance emerges rapidly in NDM-producing organisms that are treated with polymyxin alone. 2, 7, 11 Combination therapy has been proposed as a strategy to increase antimicrobial activity and reduce the emergence of resistance to polymyxins. 12, 13 Given the role of polymyxins as a treatment option of 'last resort' for infections caused by NDM-producing pathogens, investigating combinations including polymyxin is critical to maintaining its efficacy in the clinic. Chloramphenicol, which was introduced into clinics in 1949, 14 has a broad spectrum of activity that includes K. pneumoniae.
7,15
Unlike polymyxins, it is bacteriostatic and inhibits bacterial protein synthesis. 16 The aim of this study was to investigate, using clinically relevant concentrations of each antibiotic, the antibacterial activity and emergence of polymyxin resistance that were associated with polymyxin B monotherapy and combination therapy with chloramphenicol used against NDM-producing MDR K. pneumoniae.
Materials and methods

Bacterial strains and MIC measurements
Four strains of NDM-producing K. pneumoniae were examined in this study: a reference strain, ATCC BAA-2146 (ATCC, Manassas, VA, USA), and three K. pneumoniae clinical isolates (1, S01 and 129). 17 -19 The strains are described in detail in Table 1 . All the strains were MDR, which was defined as resistance to at least one antimicrobial agent from three or more antimicrobial categories. 20 The MICs of both polymyxin B (Sigma-Aldrich, Castle Hill, Australia; Batch number BCBD1065V) and chloramphenicol (Sigma-Aldrich; Batch number 02111LB) were determined for all strains in two replicates on separate days using broth microdilution in CAMHB [Ca 2+ at 22.5 mg/L and Mg 2+ at 11.25 mg/L (Oxoid, Hampshire, UK)]. 21 Susceptibility and resistance to chloramphenicol were defined as MICs of ≤8 mg/L and .8 mg/L, respectively, as per the EUCAST guidelines on Enterobacteriaceae. 22 Although no breakpoints for polymyxin B have currently been established for the Enterobacteriaceae, susceptibility and resistance breakpoints to colistin have been set at ≤2 mg/L and .2 mg/L, respectively. 22 Given the comparable activity of colistin and polymyxin B, 23 the colistin breakpoints were applied to polymyxin B for the purposes of this study.
Genotyping of NDM-producing K. pneumoniae strains
The presence of b-lactamase genes in these strains was previously investigated using PCR. 17, 24 b-Lactamases of Ambler classes A (ESBLs), B (metallo-b-lactamases) and C (extended-spectrum cephalosporinases) were examined and are presented in Table 1 . The reference strain and all three NDM-producing MDR K. pneumoniae clinical isolates contained bla NDM genes.
Bacterial genomic DNA was extracted using a DNeasy w Blood & Tissue Kit (Qiagen, USA) according to the manufacturer's instructions. The genotyping of known chloramphenicol resistance genes was carried out using standard PCR using GoTaq w Green Master Mix (M712) (Promega, Madison, USA) with the primers shown in Table S1 (available as Supplementary data at JAC Online). PCR amplifications were carried out using a T100 Thermal cycler (Bio-Rad, USA) and analysed by agarose gel electrophoresis. The published sequence for K. pneumoniae ATCC BAA-2146 was used for primer design and as a positive control. 25 
Population analysis profiles (PAPs)
PAPs were used to determine heteroresistance to polymyxins in the K. pneumoniae strains that were examined. 26 Each K. pneumoniae strain was cultured in CAMHB to an inoculum of 10 9 cfu/mL before viable counting on Mueller -Hinton agar plates containing polymyxin B (0.5, 1, 2, 4 and 8 mg/L). The plates were incubated for 24 h at 358C. The limit of detection was 20 cfu/mL (equivalent to one colony per plate). PAPs for polymyxin B were also constructed following 24 h of polymyxin B treatment in the time-kill studies (see below).
Time -kill studies
Static time -kill studies 26 were used to examine bacterial killing and the emergence of polymyxin resistance in the absence (growth controls) 
Quantification of antibacterial activity
The antibacterial activity of antibiotic monotherapies and combination therapies was quantified using two methods. The first was the change in log 10 cfu/mL (Dcfu) from 0 h to 6 and 24 h. Activity was defined as a Dcfu value ≤21, while synergy was defined as a Dcfu value ≥2 log 10 cfu/mL lower than the most active monotherapy. Additive combinations were defined as those that achieved a Dcfu value that was between .1 and ,2 log 10 cfu/mL lower than the most active monotherapy. 26 The activity of monotherapies and combination therapies was also assessed using a recently developed rate-area-shape model (equation 1). 30 log 10 cfu mL
The extent of bacterial killing is described by parameter A and the extent of bacterial regrowth by parameter B. K d describes the rate of bacterial killing and K r the rate of regrowth, while parameter C characterizes the time delay of bacterial regrowth. These parameters were then used to calculate the time to 2 log 10 killing (T2LK; equation 2) and the time to 3 log 10 regrowth (T3LR; equation 3), both of which were employed as metrics to assess the activity of each therapy.
t x−log 10 regrowth = C + 1 K r · ln x log 10 regrowth B − x log 10 regrowth (3)
To account for the sampling schedule and the duration of the time -kill study, the T2LK was constrained to ≥6.59 min and the T3LR to ≤24 h. A pooled analysis over all the concentrations was performed via analysis of covariance (ANCOVA) to differentiate between the activity and regrowth of polymyxin B and chloramphenicol monotherapy and combination therapy.
Scanning electron microscopy (SEM) of cells treated with antibiotics
A single colony of K. pneumoniae isolate 1 was used to prepare an overnight culture from which 20 mL log-phase cultures (at 10 8 cfu/mL) were obtained. Sterile stock solutions of polymyxin B and chloramphenicol were added to achieve concentrations of 2 mg/L (4×MIC) polymyxin B and 32 mg/L (8×MIC) chloramphenicol. The tubes were incubated at 378C in a shaking water bath for 1 h and then centrifuged at 3220 g for 10 min. The bacterial cells were fixed with 2.5% glutaraldehyde before being washed and resuspended three times in PBS. The bacterial cultures were incubated on polyethylenimine-coated coverslips (22 mm×22 mm) for 1 h and immersed for a further hour in 2.5% glutaraldehyde in PBS before rinsing in PBS for 10 min for three times. Dehydration was then performed using increasing concentrations of ethanol in water (10%, 30%, 50%, 70%, 90% and 100%) for 10 min in each step. The coverslips were dried in a Balzers critical point dryer (Balzers, Liechtenstein, Germany) prior to mounting on 25 mm aluminium stubs with double-sided carbon tabs. Silver liquid was applied to the edges of each coverslip, and these were then dried and goldcoated in an Edwards S150B sputter coater (Edwards High Vacuum, Crawley, West Sussex, UK). The cells were imaged with a Philips XL30 field-emission scanning electron microscope (Philips, Eindhoven, The Netherlands) at a voltage of 2 kV.
Results
Chloramphenicol resistance genotyping, MIC measurements and polymyxin heteroresistance
All the strains carried chloramphenicol resistance genes encoding the efflux pumps AcrA, EmrA and MdfA, as shown in Table 1 . All the strains except K. pneumoniae 1 also carried the eefB and oqxAB genes. The MICs of both polymyxin B and chloramphenicol are shown in Table 1 . All the strains were polymyxin heteroresistant at baseline, with the proportion of resistant bacterial cells on plates containing polymyxin B at 4 mg/L ranging from 2.4×10 27 to 1.1×10 26 ( Figure 1 ).
Microbiological response and emergence of polymyxin resistance
The time -kill curves for selected regimens of polymyxin B and chloramphenicol alone and in combination are shown in Figure 2 . The data were well explained (median R 2 ¼ 0.98 for all regimens) by the rate -area -shape model. The estimated parameters for the model (Table 2 and Table S2 ) were then used to calculate the T2LK and T3LR for each therapy examined. The growth rates were derived from the K r values for the control groups. 
Polymyxin monotherapy
Polymyxin B monotherapy produced extensive bacterial killing within 1 h against all strains, with 3 -4 log 10 cfu/mL killing at 0.5 mg/L (Table S3) 129 (chloramphenicol resistant, MDR) . The y-axis starts from the limit of detection. For isolates 1 and 129, only three time -kill curves are seen in the PAPs as there were no viable counts above the limit of detection for the two combination regimens. Symbols not seen at certain times are below the limit of detection. PMB, polymyxin B; CHL, chloramphenicol.
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regrowth was observed at all concentrations of polymyxin B examined; within 6 h, a regrowth of .3 log 10 cfu/mL was observed for all strains, and by 24 h the total bacterial populations approached those observed in the control experiments (Figure 2 ). In line with these findings, the model-derived T3LR, pooled for all the strains and concentrations that were examined, was 3.87+2.13 h. The PAPs of the bacterial regrowth at 24 h (Figure 2 , right-hand panels) revealed a large proportion of highly polymyxin-resistant cells ( 100% were able to grow on plates containing 8 mg/L polymyxin B) in all but one polymyxin monotherapy time -kill study (2 mg/L polymyxin B against K. pneumoniae S01) (Figure 2 ).
Chloramphenicol monotherapy
In the time-kill studies examining chloramphenicol alone, modest bacterial killing (up to 1.5 log 10 cfu/mL at 6 h with 16 mg/L) was achieved only against K. pneumoniae S01 (Figure 2 ). In this strain, the rate of bacterial killing for chloramphenicol was much slower than that for polymyxin B, as illustrated by T2LK values for chloramphenicol of 178 min at 8 mg/L and 416 min at 16 mg/L (compared with T2LK values for polymyxin B of 13.0 min at 1 mg/L and 12.7 min at 2 mg/L). No bacterial killing was observed for any of the remaining strains; however, an inhibition of bacterial growth (0-6 h) was observed against strain 1. Significant bacterial regrowth occurred across all the strains and chloramphenicol concentrations, with no significant differences in the total bacterial counts observed between the treated and control experiments at 24 h (Figure 2 ).
Combination therapy
The combination of chloramphenicol and polymyxin B increased the extent of bacterial killing observed in the first hour following the initiation of therapy by 1 -2 log 10 cfu/mL (Figure 2) . However, the rate of bacterial killing, as measured by the T2LK (10.6+4.37 min) assessed jointly across the combinations, did not significantly improve compared with polymyxin monotherapy (P ¼ 0.283, ANCOVA). Notably, combination therapy significantly delayed bacterial regrowth compared with polymyxin monotherapy. Bacterial regrowth, pooled for all strains and characterized by the model-estimated T3LR, for combination therapy was markedly delayed compared with that for polymyxin monotherapy (T3LR combination 19.5 h versus T3LR monotherapy 3.89 h; P, 0.01). These findings were mirrored in the Dcfu values calculated at 6 and 24 h, where synergy was observed in 25 out of 28 cases at each timepoint (Table S3 ). The emergence of polymyxinresistant bacteria was also suppressed with combination therapy at all the concentrations examined, with no colonies detected on polymyxin-containing plates following 24 h of treatment (Figure 2, right-hand panels) . Importantly, at 24 h no viable bacterial cells were detected in 15 out of 28 (54%) cases with the various combinations across all strains (Table S3) .
Morphological changes
An analysis of K. pneumoniae isolate 1 by SEM revealed morphological changes in the cell surface after treatment with each antibiotic both alone and in combination (Figure 3) . The cell surface in the untreated (control) group was relatively smooth, while the cells treated with chloramphenicol alone showed uneven surface bulges. Treatment with polymyxin B alone produced significant changes to the outer membrane, with numerous pits and protrusions. The combination treatment caused more severe cell surface damage that resembled the combined changes observed with the individual treatments. 
Discussion
As NDM-producing K. pneumoniae continues to spread globally, a lack of new antibiotics active against MDR Gram-negative bacteria in the drug development pipeline means that polymyxins will be an essential component of our antibiotic armamentarium for many years to come. 2, 7 However, the regrowth of a variety of Gram-negative organisms including K. pneumoniae with polymyxin monotherapy (both polymyxin B and colistin) has been well established both in vivo 31 and in vitro, 26,32 -34 even at concentrations far exceeding those that can be safely achieved clinically. The amplification of pre-existent polymyxin-resistant subpopulations within heteroresistant strains is known to contribute to the regrowth. 32 Adaptive resistance and the induction of genetic mutations within two-component systems involved in modifications of LPSs may also contribute. 35, 36 Combined with known suboptimal exposures to polymyxins in critically ill patients 12, 27 and dose-limiting nephrotoxicity, 12 polymyxin combination therapy has been suggested as a possible way not only to increase bacterial killing, but also to reduce the emergence of polymyxin resistance. 12, 13, 37 To date, studies utilizing time -kill methodology to examine polymyxin combinations against NDM-producing Enterobacteriaceae are virtually absent from the literature. Furthermore, the emergence of polymyxin resistance has never been examined. 38 In the present study, we systematically investigated the effectiveness of polymyxin B alone and in combination with chloramphenicol against polymyxin-susceptible NDM-producing MDR K. pneumoniae. Similarly to polymyxins, chloramphenicol fell out of favour with clinicians due to the potential adverse events, which include aplastic anaemia. 39 Chloramphenicol was chosen because it has a broad spectrum of activity against MDR organisms, including a significant subset of NDM-producing Enterobacteriaceae (up to 25% in a recent study). 7, 39, 40 In addition, chloramphenicol lacks the nephrotoxicity and exerts its antibacterial effect via a different mode of action from that of polymyxins. Figure 3 . SEM images of K. pneumoniae 1 in the absence of drug therapy (control) or in the presence of polymyxin B at 2 mg/L, chloramphenicol at 32 mg/L or the combination of these. Scale bar ¼500 nm.
The concentrations of polymyxin B employed were chosen to reflect clinically achievable unbound plasma concentrations in critically ill patients following intravenous administration of the currently recommended doses. 27, 37 For chloramphenicol, pharmacokinetic data for critically ill patients are limited. In hospitalized patients, total serum concentration of 5-20 mg/L are recommended. 29, 41 Given that chloramphenicol is 40% unbound in plasma, clinically desirable unbound chloramphenicol concentrations would be 2.3-9.4 mg/L, although free chloramphenicol concentrations of 16 -32 mg/L (which might be undesirable due to the potential side effects) have been reported. 29 The concentrations employed in the current study (4, 8, 16 and 32 mg/L) thus span the full range of clinically achievable plasma concentrations of unbound chloramphenicol.
Genes encoding multiple key efflux pumps involved in chloramphenicol resistance were present in all four strains. Three strains contained all the efflux pumps examined (i.e. AcrA, EefB, OqxAB, EmrA and MdfA) and were resistant to chloramphenicol, as indicated by the MIC results (Table 1) ; the other isolate (K. pneumoniae 1) contained only three efflux pumps and was susceptible to chloramphenicol (MIC 4 mg/L). As monotherapy, chloramphenicol merely delayed the growth of strains 1 and S01, and was completely ineffective against both strains with the highest MICs (ATCC BAA-2146 and 129); as genes for all the efflux pumps were present in isolate S01, other underlying mechanisms of resistance and/or other efflux pumps may be present in ATCC BAA-2146 and isolate 129. Nevertheless, all polymyxin B/chloramphenicol combinations substantially enhanced bacterial killing against all the strains irrespective of the chloramphenicol MIC ( Figure 2 and Table S3 ). Importantly, although both polymyxin B monotherapy and the combinations produced rapid and extensive bacterial killing within the first 1-2 h following antibiotic exposure, in all cases the subsequent rapid regrowth observed with polymyxin B monotherapy was either substantially reduced by combination therapy or, in 54% of cases, entirely eliminated ( Figure 2 and Table S3 ). That even low concentrations of polymyxin B (e.g. 0.5 mg/L) can prevent or minimize regrowth is an important finding given that polymyxin-induced nephrotoxicity is the dose-limiting adverse effect. Additionally, and in stark contrast to polymyxin B monotherapy, no emergence of resistance to polymyxin B across 24 h was observed with any combination even when regrowth occurred.
After treatment with polymyxin B alone, the formation of projections and blebs on the surface of K. pneumoniae 1 cells indicated a pronounced disruption of the structural integrity of the bacterial outer membrane (Figure 3 ). These observations are consistent with its mode of action, which is centred on the bacterial membrane and membrane-anchored lipid A. 42 These changes in the outer membrane have been reported after treatment with polymyxins against other bacteria including Escherichia coli, 43, 44 Salmonella typhimurium 43, 45 and Pseudomonas aeruginosa.
44,46
While previous investigations using other bacterial species such as E. coli and P. aeruginosa have not shown significant morphological changes following treatment with chloramphenicol as monotherapy, 46 morphological changes in the form of convoluted surfaces were observed in the present study. The combination of polymyxin B and chloramphenicol caused even more dense projections, morphologically a combination of the changes caused by polymyxin B and chloramphenicol alone (Figure 3 ). Our SEM results also support the synergistic killing of polymyxin B with chloramphenicol.
Two mechanisms, namely subpopulation synergy and mechanistic synergy, have been proposed to explain the enhanced pharmacodynamic effects seen with polymyxin combination therapy. 47 Subpopulation synergy involves the killing of a subpopulation resistant to one drug in combination with the second drug and vice versa, whereas mechanistic synergy involves two drugs in a combination acting on different cellular pathways in the same organism to increase the rate and extent of killing of the other drug. We have demonstrated, for the first time, the phenomenon of polymyxin heteroresistance in strains of NDM-producing K. pneumoniae ( Figure 1) ; as has been previously observed, the presence of highly polymyxin-resistant cells is likely to be a key contributor to the regrowth that was observed in our study following polymyxin monotherapy (Figure 2) . Interestingly, for isolate 129, no bacterial killing was observed following exposure to chloramphenicol monotherapy at 32 mg/L, with the bacterial density reaching that of the control at 24 h. However, a reduction of 2 log 10 cfu/mL lower than the initial inoculum was achieved with the same regimen against a polymyxin-resistant subpopulation taken from the same isolate (data not shown). This suggests that at least part of the improvement in bacterial killing observed by the addition of chloramphenicol to polymyxin B may be due to chloramphenicol acting on the polymyxin-resistant subpopulation that was present in the heteroresistant strains.
In summary, this study is the first to show the existence of polymyxin heteroresistance within NDM-producing K. pneumoniae and to demonstrate that polymyxin B in combination with chloramphenicol at clinically relevant concentrations significantly enhances bacterial killing. Notably, the combination suppressed the emergence of polymyxin-resistant subpopulations over a 24 h period. Further studies are warranted to investigate the effect of chloramphenicol resistance genes (e.g. the chloramphenicol acetyltransferase gene) on synergistic killing with polymyxins and to optimize combination therapy against NDM-producing 'superbugs' using animal infection models. As this information becomes available, its translation into the clinic should prolong the efficacy of these important last-line antibiotics.
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